Welcome to our blog on precision oncology, "Cancer is Personal", a space dedicated to exploring how personalized, data-driven cancer treatments are transforming cancer care, improving outcomes, and minimizing side effects.

Search by Resource Topic:
Sort by Date Posted:
Search by Keywords:

Why Cancers Stop Responding to Treatment: Understanding Tumor Heterogeneity and Resistance

Introduction Over the last few articles we have been taking a close look at how molecular testing is changing the way papillary thyroid cancer is diagnosed and treated. Today we are going to zoom out and look at a challenge that affects patients across almost every cancer type, and one that gets to the heart […]

Kira Grewal, MSc
September 2, 2026

5 min read

Qualisure Diagnostics and Invitrocue Announce Strategic Collaboration to Advance RNA-Based Precision Oncology Across Singapore and ASEAN

PRESS RELEASE Calgary, Canada and Singapore — 2026-08-21 Qualisure Diagnostics Inc. and Invitrocue today announced a strategic collaboration to introduce Thyroid GuidePx®, Qualisure’s RNA-based diagnostic for papillary thyroid cancer, to Singapore and the broader ASEAN region. The collaboration combines Qualisure’s expertise in RNA-based diagnostics with Invitrocue’s established capabilities in precision medicine, advanced laboratory services, and […]

Dave Ehman P.Eng., CISSP
August 21, 2026

3 min read

Avoiding a Second Surgery: How Thyroid GuidePx® Can Help Patients Skip the Completion Thyroidectomy

Introduction For many patients diagnosed with papillary thyroid cancer, the first surgery is not always the only one. A significant number of people who have a lobectomy, where only part of the thyroid is removed, find themselves needing a second operation just weeks later to remove the rest of the gland. This second surgery is […]

Kira Grewal, MSc
July 30, 2026

6 min read

Molecular Risk Testing: A Smarter System for Thyroid Cancer Care

Bathe, O. F. Open Access Govt July 2026. Published on 2026-06-03 Abstract Molecular risk testing: A smarter system for thyroid cancer care. Oliver Bathe, Professor of Surgery and Oncology at the University of Calgary and CEO of Qualisure Diagnostics, calls for policymakers to support molecular risk testing to improve patient care and reduce the healthcare […]

Kira Grewal, MSc
July 17, 2026

1 min read

Thyroid GuidePx®: A Smarter Way to Understand Papillary Thyroid Cancer

Introduction Papillary thyroid cancer is the most common type of thyroid cancer, and its incidence is increasing by approximately 6% every year. For most patients, the prognosis is good. But good odds on a population level do not always translate into clarity for the individual patient sitting in a clinic, trying to understand what their […]

Kira Grewal, MSc
June 24, 2026

6 min read

Gene Expression Panels: Listening to What Your Tumor Is Doing

Introduction When most people think about cancer testing, they think about looking for something specific. A mutation, a protein, a genetic change. The tests we explored in our previous articles largely work this way: they scan a tumor for a known target and tell you whether it is there or not. But what if the […]

Kira Grewal, MSc
May 27, 2026

4 min read
No more posts to show